Artelo Biosciences, Inc.

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The company's mission is to address significant unmet medical needs across various diseases and conditions. Headquartered in Solana Beach, California, Artelo Biosciences leverages scientific, regulatory, and commercial expertise to advance its pipeline.

The company's diversified pipeline includes several key product candidates. ART27.13, a synthetic cannabinoid agonist, is in Phase 1b/2a clinical trials for cancer-related anorexia-cachexia syndrome and is also being explored for glaucoma and as a potential companion therapy to GLP-1 treatments. ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor, is under development for chemotherapy-induced peripheral neuropathy, pain, inflammation, anxiety, and dermatologic conditions. Additionally, ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine, is targeted for anxiety, depression, post-traumatic stress disorder (PTSD), epilepsy, insomnia, and other neurological disorders.

Recent notable developments for Artelo Biosciences include a strategic collaboration with AI company ScienceMachine in April 2026 to enhance its FABP5 inhibitor program. The company also announced a peer-reviewed publication supporting ART26.12 as a novel pain treatment in April 2026 and regained compliance with Nasdaq listing requirements in the same month. In March 2026, Artelo expanded its clinical pipeline into the glaucoma market with a fully funded clinical study for ART27.13. Furthermore, positive interim Phase 2 data for ART27.13 in cancer anorexia-cachexia syndrome, reported in September 2025, has generated significant partnering interest. Gregory D. Gorgas serves as the President and CEO, leading the company's efforts to bring high-impact therapies to market.